Lowering Drug Prices: A Blueprint for Reform lays out the steps a President committed to addressing excessively high drug prices could take to bring down prices without congressional action.
Excessively high drug prices put many Americans in the impossible position of choosing between health and financial security. There are many proposals in Congress to address high drug prices, but policymakers’ deep ties to the pharmaceutical industry stand as barriers to congressional action. Fortunately, there are several actions a presidential administration could take to help lower prescription drug prices without Congress. In this paper Margetta Morgan and Sterling explore the rules that skew the drug development and approval process to prioritize shareholder value over the American people and lay out the actions a President committed to addressing this issue could take.